List – 54 Drug Patents that are Expiring in 2024
With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible, and keeping that very thought in mind, we collated a list of 54 drugs that are going off-patent in 2024. We also included other information like yearly sales, dosage information, ingredients, and the diseases they cure. This could help you easily choose the most profitable drug to develop a generic version of.
Loved the idea and the list? Thank us later in the comments section. Now onto the list.
The article has a list of drug patents expiring in 2024. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
[/vc_column_text][/vc_column][/vc_row]
Drug Patents Expiring in 2024
Mulpleta
Lusutrombopag
Lusutrombopag
Sales:
200 Million Yen (2018)
200 Million Yen (2018)
| Patents | Expiration Date |
|---|---|
| US7601746 | September 05, 2024 |
| US8889722 | July 29, 2028 |
| US8530668 | January 21, 2030 |
Dosage: Oral
Company: Shionogi Inc.
Ingredients: LUSUTROMBOPAG
Treatment: Thrombocytopenia
Invokamet XR
Canagliflozin; Metformin Hydrochloride
Canagliflozin; Metformin Hydrochloride
Sales:
$1.41 Billion (2016)
$1.41 Billion (2016)
| Patents | Expiration Date |
|---|---|
| US8785403 | July 30, 2024 |
| US8222219 | March 11, 2025 |
Dosage: Tablet, Extended Release; Oral
Company: Janssen Pharmaceuticals Inc
Ingredients: Canagliflozin; Metformin Hydrochloride
Treatment: Type 2 Diabetes Mellitus
Revlimid
Lenalidomide
Lenalidomide
Sales:
$10.82 Billion (2019)
$10.82 Billion (2019)
| Patents | Expiration Date |
|---|---|
| US7855217 | November 24, 2024 |
| US7465800 | April 27, 2027 |
Dosage: Oral
Company: Celgene Corp
Ingredients: LENALIDOMIDE
Treatment: Multiple Myeloma and Myelodysplastic Syndromes
Rydapt
Midostaurin
Midostaurin
Sales:
$150 Million (2018)
$150 Million (2018)
| Patents | Expiration Date |
|---|---|
| US7973031 | October 17, 2024 |
| US8222244 | October 29, 2022 |
Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Midostaurin
Treatment: Acute Myeloid Leukemia
Prevymis
Letermovir
Letermovir
Sales:
$370 Million (2020)
$370 Million (2020)
| Patents | Expiration Date |
|---|---|
| US7196086 | May 22, 2024 |
| US8513255 | May 22, 2024 |
Dosage: Solution; Intravenous
Company: Merck Sharp And Dohme Corp
Ingredients: Letermovir
Treatment: Cytomegalovirus (CMV) infection
Vyndaqel
Tafamidis Meglumine
Tafamidis Meglumine
Sales:
$259 Million (Jan-Sep 2019)
$259 Million (Jan-Sep 2019)
| Patents | Expiration Date |
|---|---|
| US7214695 | April 27, 2024 |
| US7214696 | December 19, 2023 |
| US8168663 | December 19, 2023 |
| US8653119 | January 28, 2024 |
Dosage: Capsule; Oral
Company: Foldrx Pharmaceuticals Inc Sub Pfizer Inc
Ingredients: Tafamidis Meglumine
Treatment: Transthyretin Amyloid Polyneuropathy
Lynparza
Olaparib
Olaparib
Sales:
$847 Million (2018)
$847 Million (2018)
| Patents | Expiration Date |
|---|---|
| US7151102 | April 29, 2022 |
| US7449464 | October 11, 2024 |
| US7981889 | October 11, 2024 |
| US8912187 | March 12, 2024 |
Dosage: Capsule; Oral
Company: AstraZeneca Pharmaceuticals LP
Ingredients: Olaparib
Treatment: Advanced Ovarian Cancer, Fallopian Tube Cancer
Tasigna
Nilotinib
Nilotinib
Sales:
$1.88 Billion (2019)
$1.88 Billion (2019)
| Patents | Expiration Date |
|---|---|
| US7169791 | January 04, 2024 |
| US8415363 | January 18, 2027 |
| US8163904 | February 23, 2029 |
| US9061029 | October 7, 2032 |
Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Nilotinib Hydrochloride
Treatment: Chronic Myelogenous Leukemia
Xopenex HFA
Levalbuterol Tartrate
Levalbuterol Tartrate
Sales:
$148 Million (2012)
$148 Million (2012)
| Patents | Expiration Date |
|---|---|
| US7256310 | October 08, 2024 |
Dosage: Aerosol, Metered; Inhalation
Company: Sunovion Pharmaceuticals Inc
Ingredients: Levalbuterol Tartrate
Treatment: Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Vandazole
Metronidazole
Metronidazole
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7456207 | September 22, 2024 |
Dosage: Gel; Vaginal
Company: Teva Pharmaceuticals USA
Ingredients: Metronidazole
Treatment: Bacterial Vaginosis
Prialt
Ziconotide Acetate
Ziconotide Acetate
Sales:
$27 Million (2017)
$27 Million (2017)
| Patents | Expiration Date |
|---|---|
| US8653033 | October 10, 2024 |
| US8765680 | October 10, 2024 |
| US9707270 | October 10, 2024 |
Dosage: Injectable; Intrathecal
Company: TerSera Therapeutics LLC
Ingredients: Ziconotide Acetate
Treatment: Pain Reliever
Aloxi
Palonosetron Hydrochloride
Palonosetron Hydrochloride
Sales:
$400 Million (2019)
$400 Million (2019)
| Patents | Expiration Date |
|---|---|
| US7947724 | January 30, 2024 |
| US7947725 | January 30, 2024 |
| US7960424 | January 30, 2024 |
| US8518981 | January 30, 2024 |
| US8598218 | January 30, 2024 |
| US9173942 | January 30, 2024 |
| US9439854 | January 30, 2024 |
| US9457020 | January 30, 2024 |
Dosage: Injectable; Intravenous
Company: Helsinn Healthcare SA
Ingredients: Palonosetron Hydrochloride
Treatment: Acute Nausea and Vomiting
Dificid
Fidaxomicin
Fidaxomicin
Sales:
$60 Million (2021)
$60 Million (2021)
| Patents | Expiration Date |
|---|---|
| US8586551 | January 23, 2024 |
| US7378508 | January 31, 2028 |
| US7863249 | January 31, 2028 |
Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: FIDAXOMICIN
Treatment: Clostridioides difficile-associated Diarrhea (CDAD)
Linzess
Linaclotide
Linaclotide
Sales:
$287 Million (2021)
$287 Million (2021)
| Patents | Expiration Date |
|---|---|
| US7371727 | January 28, 2024 |
| US7745409 | January 28, 2024 |
| US8080526 | January 28, 2024 |
| US7704947 | January 28, 2024 |
| US7304036 | August 30, 2026 |
Dosage: Oral
Company: Allergan
Ingredients: LINACLOTIDE
Treatment: Irritable Bowel Syndrome
Myfembree
Relugolix/estradiol/norethisterone acetate
Relugolix/estradiol/norethisterone acetate
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7300935 | January 28, 2024 |
| US8058280 | January 28, 2024 |
Dosage: Oral
Company: Myovant Sciences
Ingredients: ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Treatment: Heavy Menstrual Bleeding
Ferric Citrate
Ferric Citrate
Ferric Citrate
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US9328133 | February 18, 2024 |
| US9757416 | February 18, 2024 |
| US8338642 | February 18, 2024 |
| US7767851 | February 18, 2024 |
Dosage: Oral
Company: Akebia Therapeutics
Ingredients: FERRIC CITRATE
Treatment: Hyperphosphataemia and Iron Deficiency Anaemia
Ofev/Vargatef
Nintedanib
Nintedanib
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7119093 | February 21, 2024 |
| US6762180 | October 1, 2025 |
Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: NINTEDANIB ESYLATE
Treatment: Idiopathic Pulmonary Fibrosis
Isentress
Raltegravir
Raltegravir
Sales:
$857 Million (2020)
$857 Million (2020)
| Patents | Expiration Date |
|---|---|
| US7119093 | February 21, 2024 |
| US6762180 | October 1, 2025 |
Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: RALTEGRAVIR POTASSIUM
Treatment: HIV/AIDS
Zontivity
Vorapaxar
Vorapaxar
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7304078 | April 6, 2024 |
| US7713999 | May 30, 2024 |
Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: VORAPAXAR SULFATE
Treatment: Peripheral Arterial Disease
Bosulif
Bosutinib
Bosutinib
Sales:
$23 Million (2020)
$23 Million (2020)
| Patents | Expiration Date |
|---|---|
| USRE42376 | April 13, 2024 |
| US7767678 | November 23, 2026 |
Dosage: Oral
Company: Pfizer
Ingredients: BOSUTINIB MONOHYDRATE
Treatment: Chronic Myelogenous Leukemia
Omontys
Peginesatide
Peginesatide
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7084245 | May 12, 2024 |
| US7414105 | May 12, 2024 |
| US7919118 | May 12, 2024 |
| US7528104 | May 12, 2024 |
Dosage: Subcutaneous, intravenous
Company: Affymax Inc.
Ingredients: PEGINESATIDE ACETATE
Treatment: Anemia
Aliqopa
Copanlisib
Copanlisib
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7511041 | May 13, 2024 |
| USRE46856 | October 22, 2029 |
| US10383876 | March 29, 2032 |
Dosage: Intravenous infusion
Company: Bayer
Ingredients: COPANLISIB DIHYDROCHLORIDE
Treatment: Relapsed follicular lymphoma
Mayzent
Siponimod
Siponimod
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7939519 | May 19, 2024 |
Dosage: Oral
Company: Novartis
Ingredients: SIPONIMOD FUMARIC ACID
Treatment: Multiple Sclerosis
Prevymis
Letermovir
Letermovir
Sales:
$281 Million (2020)
$281 Million (2020)
| Patents | Expiration Date |
|---|---|
| US8513255 | May 22, 2024 |
| USRE46791 | May 22, 2024 |
Dosage: Oral, Intravenous
Company: Merck & Co
Ingredients: LETERMOVIR
Treatment: Cytomegalovirus
Xifaxan
Rifaximin
Rifaximin
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7612199 | June 19, 2024 |
| US8835452 | June 19, 2024 |
| US8158781 | June 19, 2024 |
| US7045620 | June 19, 2024 |
| US7902206 | June 19, 2024 |
| US7906542 | June 1, 2025 |
| US8741904 | February 27, 2026 |
| US8193196 | September 2, 2027 |
Dosage: Oral
Company: Salix Pharmaceuticals
Ingredients: RIFAXIMIN
Treatment: Travelers’ Diarrhea, Irritable Bowel Syndrome
Remodulin/Orenitram/Tyvaso
Treprostinil
Treprostinil
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US9050311 | May 24, 2024 |
| US7417070 | July 30, 2026 |
| US8497393 | December 15, 2028 |
Dosage: Subcutaneous, intravenous, inhalation, Oral
Company: United Therapeutics
Ingredients: TREPROSTINIL DIOLAMINE
Treatment: Pulmonary arterial hypertension
Tpoxx
Tecovirimat
Tecovirimat
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US8124643 | June 18, 2024 |
| US9339466 | March 23, 2031 |
Dosage: Oral
Company: SIGA Technologies
Ingredients: TECOVIRIMAT
Treatment: Orthopoxviruses (Smallpox and Monkeypox)
Nuvigil
Armodafinil
Armodafinil
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7132570 | June 18, 2024 |
Dosage: Oral
Company: Teva Pharmaceuticals
Ingredients: ARMODAFINIL
Treatment: Excessive Daytime Sleepiness
Oriahnn
Elagolix/estradiol/norethindrone acetate
Elagolix/estradiol/norethindrone acetate
Sales:
$145 Million (2021)
$145 Million (2021)
| Patents | Expiration Date |
|---|---|
| US7419983 | July 6, 2024 |
| US7056927 | September 10, 2024 |
Dosage: Oral
Company: AbbVie Inc.
Ingredients: ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
Treatment: Heavy Menstrual Bleeding
Xeglyze
Abametapir
Abametapir
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US9839631 | July 16, 2024 |
Dosage: Topical
Company: Dr. Reddy’s Laboratories
Ingredients: ABAMETAPIR
Treatment: Head Lice Infestation
Ninlaro
Ixazomib
Ixazomib
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US8546608 | August 12, 2024 |
| US8003819 | August 6, 2027 |
| US8530694 | August 6, 2027 |
| US7687662 | August 6, 2027 |
| US8859504 | June 16, 2029 |
| US7442830 | November 20, 2029 |
Dosage: Oral
Company: Takeda
Ingredients: IXAZOMIB CITRATE
Treatment: Multiple Myeloma
Prezista
Darunavir
Darunavir
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US8518987 | August 16, 2024 |
| US7700645 | June 26, 2027 |
Dosage: Oral
Company: Janssen Therapeutics
Ingredients: DARUNAVIR
Treatment: HIV/AIDS
Xarelto
Rivaroxaban
Rivaroxaban
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7157456 | August 28, 2024 |
Dosage: Oral
Company: Janssen Therapeutics
Ingredients: RIVAROXABAN
Treatment: Blood clots
MoviPrep
POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7169381 | September 1, 2024 |
| US7658914 | September 1, 2024 |
Dosage: Oral
Company: Velinor A.G
Ingredients: ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE
Treatment: Use for Colonoscopy Bowel Preparation
Aldara
Imiquimod
Imiquimod
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7696159 | October 1, 2024 |
Dosage: Topical
Company: 3M Pharmaceutical
Ingredients: IMIQUIMOD
Treatment: Genital Warts, Superficial Basal cell carcinoma, and Actinic Keratosis
Brilinta
Ticagrelor
Ticagrelor
Sales:
$1.4 Billion (2021)
$1.4 Billion (2021)
| Patents | Expiration Date |
|---|---|
| USRE46276 | October 30, 2024 |
Dosage: Oral
Company: AstraZeneca
Ingredients: TICAGRELOR
Treatment: Stroke, Heart Attack
Xiidra
Lifitegrast
Lifitegrast
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7745460 | November 5, 2024 |
| US7928122 | November 5, 2024 |
| US7314938 | March 10, 2025 |
| US8084047 | May 17, 2026 |
| US9890141 | October 21, 2030 |
Dosage: Eye Drops
Company: Novartis
Ingredients: LIFITEGRAST
Treatment: Signs and Symptoms of Dry Eye
Nourianz
Istradefylline
Istradefylline
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7541363 | November 13, 2024 |
Dosage: Oral
Company: Kyowa Kirin Co.
Ingredients: ISTRADEFYLLINE
Treatment: Levodopa/Carbidopa in adults with Parkinson’s disease
Ponvory
Ponesimod
Ponesimod
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| USRE43728 | November 16, 2024 |
| US9062014 | May 6, 2032 |
Dosage: Oral
Company: Janssen Pharmaceuticals
Ingredients: PONESIMOD
Treatment: Multiple Sclerosis
Tukysa
Tucatinib
Tucatinib
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7452895 | November 16, 2024 |
| US8648087 | April 12, 2031 |
Dosage: Oral
Company: Seagen Inc
Ingredients: TUCATINIB
Treatment: HER2-positive Breast Cancer
Asclera/Aethoxysklerol/Varithena
Polidocanol
Polidocanol
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7731986 | November 17, 2024 |
Dosage: Topical, Subcutaneous Injection
Company: Methapharm, Inc.
Ingredients: POLIDOCANOL
Treatment: Itching caused by Eczema and Dry Skin
Zepzelca
Lurbinectedin
Lurbinectedin
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7763615 | December 13, 2024 |
Dosage: Intravenous Injection
Company: PharmaMar, S.A.
Ingredients: LURBINECTEDIN
Treatment: Metastatic Small Cell Lung Cancer (SCLC)
Victrelis
Boceprevir
Boceprevir
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| USRE43298 | December 22, 2024 |
Dosage: Oral
Company: Merck & Co
Ingredients: BOCEPREVIR
Treatment: Hepatitis caused by Hepatitis C virus (HCV) genotype 1
Conclusion
As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.
With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.
Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team
Great report.